- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Interventions
- cabozantinib, abiraterone, prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
- Interventions
- Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Interventions
- Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 63
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone, Sunitinib, Dasatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Drug
- Lead sponsor
- DisperSol Technologies, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more
- Conditions
- Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • La Jolla, California • Santa Monica, California + 14 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Daniel George, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- New Orleans, Louisiana • Baltimore, Maryland • Detroit, Michigan + 11 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone, Enzalutamide, LHRHa
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Martha Mims
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- abiraterone acetate, dasatinib, prednisone
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Prednisone, Computed Tomography, Bone Scan, Biospecimen Collection, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 14
- States / cities
- Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- PLX2853 20 mg, Olaparib, Abiraterone acetate, Prednisone, PLX2853 40 mg, PLX2853 80 mg
- Drug
- Lead sponsor
- Opna Bio LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Detroit, Michigan • New York, New York + 4 more
- Conditions
- Prostate Cancer, Prostatic Neoplasm
- Interventions
- abiraterone acetate in combination with prednisone
- Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 45
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Tucson, Arizona + 42 more
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Neoplasms
- Interventions
- Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Buffalo, New York • Myrtle Beach, South Carolina • San Antonio, Texas
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide Acetate, Prednisone, Docetaxel, Apalutamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets, MCLA-128
- Drug · Biological
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 665
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
- Interventions
- Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 925 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 63
- States / cities
- Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
- Drug · Procedure · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia